国际口腔医学杂志

国际口腔医学杂志 ›› 2017, Vol. 44 ›› Issue (1): 83-86.doi: 10.7518/gjkq.2017.01.017

• ·综述· • 上一篇    下一篇

颌面头颈部骨肉瘤化学治疗的研究进展

李晓, 季彤   

  1. 上海交通大学医学院附属第九人民医院口腔颌面头颈肿瘤科上海市口腔医学重点实验室 上海 200011
  • 收稿日期:2016-02-06 出版日期:2017-01-01 发布日期:2017-01-01
  • 通讯作者: 季彤,教授,博士,Email：jitongjitong@foxmail.com
  • 作者简介:李晓,硕士,Email：lixiao1991@yeah.net
  • 基金资助:
    上海高校高峰高原学科建设项目（2016）

Chemotherapy in the treatment of osteosarcoma in oral maxillofacial-head and neck region

Li Xiao, Ji Tong.   

  1. Dept. of Oral and Maxillofacial-Head and Neck Tumor, The Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
  • Received:2016-02-06 Online:2017-01-01 Published:2017-01-01

RichHTML

4

PDF (PC)

507

被引次数

1

摘要： 骨肉瘤是颌面头颈部较为罕见的恶性肿瘤之一,包括局部切除手术及辅助放化学治疗在内的综合序列治疗是现阶段最有效的治疗方法。化学治疗是综合序列治疗的重要组成部分。在目前已有的化学治疗方案中,甲氨蝶呤、阿霉素和顺铂（MAP）等经典化学治疗方案在口腔颌面头颈部骨肉瘤的治疗中有重要的作用;此外,新辅助化学治疗和电化学疗法等方案也在近年诞生,然而其临床应用价值尚待考证。随着近年来对骨肉瘤分子生物学认知的逐步深入,在分子生物学水平上探讨针对肿瘤细胞的化学药物成为新的进展趋势。本文就化学治疗在颌面头颈部骨肉瘤治疗中应用的研究进展作一综述。

关键词: 骨肉瘤, 化学疗法, 口腔颌面部

Abstract: Osteosarcoma is one of the rare malignant tumors in the maxillofacial region. Synthetic sequential therapy including radical resection and adjuvant radio-chemotherapy is the most effective currently. Chemotherapy is an important part in synthetic sequential therapy. In the existing chemotherapy regimens, traditional chemotherapy such as MAP(methotrexate, adriacin, cisplatin) plays a key role in the treatment of osteosarcoma in oral maxillofacial-head and neck region. In addition, some other regimens such as neoadjuvant chemotherapy, electrochemical therapy are also proposed in recent years, but their effectiveness remains to be investigated. Chemotherapy has a significant effect on improving the prognosis of osteosarcoma. With the gradual development of the cognition of osteosarcoma molecular biology in recent years, it has become a new trend to study the chemical drugs for tumor cells in the level of molecular biology. This paper reviews the application of chemotherapy in the treatment of osteosarcoma in oral and maxillofacial- head and neck region.

Key words: osteosarcoma, chemotherapy, oral and maxillofacial region

中图分类号: 

  • R739.82
[1] 郭伟. 头颈肿瘤诊断治疗学[M]. 北京: 人民军医出版社, 2013:196-207. Guo W. Diagnosis and treatment of head and neck cancer[M]. Beijing: People’s Military Medical Press, 2013:196-207.
[2] Taghavi N, Mehrdad L, Rajabi M, et al. A 10-year retrospective study on malignant jaw tumors in Iran [J]. J Craniofac Surg, 2010, 21(6):1816-1819.
[3] van den Berg H, Merks JH. Incidence and grading of cranio-facial osteosarcomas[J]. Int J Oral Maxillofac Surg, 2014, 43(1):7-12.
[4] Wang S, Shi H, Yu Q. Osteosarcoma of the jaws: demographic and CT imaging features[J]. Dentoma-xillofac Radiol, 2012, 41(1):37-42.
[5] Kämmerer PW, Shabazfar N, Vorkhshori Makoie N, et al. Clinical, therapeutic and prognostic features of osteosarcoma of the jaws-experience of 36 cases[J]. J Craniomaxillofac Surg, 2012, 40(6):541-548.
[6] Argon A, Doğanavşargıl B, Ünal Yıldırım F, et al. Osteosarcomas of jaw: experience of a single centre [J]. J Plast Surg Hand Surg, 2015, 49(1):13-18.
[7] Mücke T, Mitchell DA, Tannapfel A, et al. Effect of neoadjuvant treatment in the management of osteo-sarcomas of the head and neck[J]. J Cancer Res Clin Oncol, 2014, 140(1):127-131.
[8] Miwa S, Takeuchi A, Shirai T, et al. Prognostic value of radiological response to chemotherapy in patients with osteosarcoma[J]. PLoS One, 2013, 8(7):e70015.
[9] Sakamoto A, Iwamoto Y. Current status and perspec-tives regarding the treatment of osteosarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008, 3(3): 228-231.
[10] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1):89-99.
[11] Meyers PA, Schwartz CL, Krailo MD, et al. Osteo-sarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group[J]. J Clin Oncol, 2008, 26(4):633-638.
[12] Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group[J]. Cancer, 2009, 115(22):5339-5348.
[13] Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century[J]. J Clin Oncol, 2010, 28(15):2625-2634.
[14] Anninga JK, Gelderblom H, Fiocco M, et al. Chemo-therapeutic adjuvant treatment for osteosarcoma: where do we stand[J]. Eur J Cancer, 2011, 47(16): 2431-2445.
[15] Daw NC, Neel MD, Rao BN, et al. Frontline treat-ment of localized osteosarcoma without methotrexate [J]. Cancer, 2011, 117(12):2770-2778.
[16] 邱蔚六, 郑家伟. 应重视口腔颌面部恶性肿瘤的综合序列治疗[J]. 中国口腔颌面外科杂志, 2005, 3 (3):179-182. Qiu WL, Zheng JW. Comprehensive and sequential therapy for oral and maxillofacial malignancies: an evolving concept and clinical significance[J]. Chin J Oral Maxillofac Surg, 2005, 3(3):179-182.
[17] Granowski-LeCornu M, Chuang SK, Kaban LB, et al. Osteosarcoma of the jaws: factors influencing prognosis[J]. J Oral Maxillofac Surg, 2011, 69(9): 2368-2375.
[18] Thariat J, Julieron M, Brouchet A, et al. Osteosar-comas of the mandible: are they different from other tumor sites[J]. Crit Rev Oncol Hematol, 2012, 82(3): 280-295.
[19] Thariat J, Schouman T, Brouchet A, et al. Osteosar-comas of the mandible: multidisciplinary manage-ment of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013, 24(3):824-831.
[20] Mali B, Jarm T, Snoj M, et al. Antitumor effective-ness of electrochemotherapy: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2013, 39(1): 4-16.
[21] Campana LG, Bertino G, Rossi CR, et al. The value of electrochemotherapy in the treatment of peristomal tumors[J]. Eur J Surg Oncol, 2014, 40(3):260-262.
[22] Isobe K, Shimizu T, Nikaido T, et al. Low-voltage electrochemotherapy with low-dose methotrexate enhances survival in mice with osteosarcoma[J]. Clin Orthop Relat Res, 2004(426):226-231.
[23] Mücke T, Mitchell DA, Tannapfel A, et al. Outcome in adult patients with head and neck sarcomas—a 10-year analysis[J]. J Surg Oncol, 2010, 102(2):170- 174.
[24] Mendenhall WM, Fernandes R, Werning JW, et al. Head and neck osteosarcoma[J]. Am J Otolaryngol, 2011, 32(6):597-600.
[25] 李江, 何荣根. 颌面部骨肉瘤61例临床病理研究[J]. 中华口腔医学杂志, 2003, 38(6):444-446. Li J, He RG. Osteosarcoma of maxillofacial area: a clinicopathological study of 61 cases[J]. Chin J Stomatol , 2003, 38(6):444-446.
[26] Smith RB, Apostolakis LW, Karnell LH, et al. Na-tional Cancer Data Base report on osteosarcoma of the head and neck[J]. Cancer, 2003, 98(8):1670- 1680.
[27] Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979—2007[J]. Int J Cancer, 2012, 131(4):E508- E517.
[28] Junior AT, de Abreu Alves F, Pinto CA, et al. Clini-copathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas[J]. Oral Oncol, 2003, 39(5):521-530.
[29] Eid A, Li S, Garza R, et al. Chemotherapy for oral and maxillofacial tumors: an update[J]. Oral Maxi-llofac Surg Clin North Am, 2014, 26(2):163-169.
[30] Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment-where do we stand? A state of the art review[J]. Cancer Treat Rev, 2014, 40(4):523-532.
[31] Kuba K, Inoue H, Hayashi T, et al. Laryngeal osteo-sarcoma: case report and literature review[J]. Head Neck, 2015, 37(2):E26-E29.
[32] Beckingsale TB, Gerrand CH. Osteosarcoma[J]. Orthopaed Trauma, 2010, 24(5):321-331.
[33] Park HR, Cabrini RL, Araujo ES, et al. Expression of ezrin and metastatic tumor antigen in osteo-sarcomas of the jaw[J]. Tumori, 2009, 95(1):81-86.
（本文采编 王晴）
[1] 戴清仪,郝昊,华成舸,黄波,杨征. 口腔及颅颌面部常见运动防护用具的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 366-373.
[2] 木合森·牙生江,买买提吐逊·吐尔地. 带线锚钉在口腔颌面外科的应用[J]. 国际口腔医学杂志, 2023, 50(1): 114-119.
[3] 佘杨杨, 农晓琳. A型肉毒杆菌毒素在口腔颌面部的临床应用[J]. 国际口腔医学杂志, 2017, 44(6): 707-711.
[4] 郭文豪,游梦,罗晶晶,王凯利,王虎,郑广宁. 4例口腔颌面部非霍奇金淋巴瘤的影像学表现[J]. 国际口腔医学杂志, 2016, 43(2): 146-150.
[5] 罗志强, 南晓梅 叶钟泰. 2 085例口腔颌面部肿瘤疾病构成比分析[J]. 国际口腔医学杂志, 2015, 42(6): 635-639.
[6] 王艳颖综述 宫苹审校. 组织工程技术修复口腔颌面部神经损伤的研究进展[J]. 国际口腔医学杂志, 2010, 37(3): 314-314～316，319.
[7] 刘奕杉1，凌彬2，马旭东3，王善征3，林兆全2，刘耕3. E-cad和CD44v6在口腔鳞癌中的表达及意义[J]. 国际口腔医学杂志, 2007, 34(05): 325-327.
[8] 陈志方,陈传俊. 穿支皮瓣及其在口腔颌面部的应用[J]. 国际口腔医学杂志, 2005, 32(04): 303-304.
[9] 崔敏毅. 口腔颌面部CT三维技术的应用与进展[J]. 国际口腔医学杂志, 2004, 31(S1): -.
[10] 郅克谦,李良忠. 颌骨肉瘤诊断和治疗的进展[J]. 国际口腔医学杂志, 2002, 29(04): -.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张新春. 桩冠修复与无髓牙的保护[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 王昆润. 长期单侧鼻呼吸对头颅发育有不利影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 彭国光. 颈淋巴清扫术中颈交感神经干的解剖变异[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 杨凯. 淋巴化疗的药物运载系统及其应用现状[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 康非吾. 种植义齿下部结构生物力学研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 柴枫. 可摘局部义齿用Co-Cr合金的激光焊接[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 孟姝,吴亚菲,杨禾. 伴放线放线杆菌产生的细胞致死膨胀毒素及其与牙周病的关系[J]. 国际口腔医学杂志, 2005, 32(06): 458 -460 .
[8] 费晓露,丁一,徐屹. 牙周可疑致病菌对口腔黏膜上皮的粘附和侵入[J]. 国际口腔医学杂志, 2005, 32(06): 452 -454 .
[9] 赵兴福,黄晓晶. 变形链球菌蛋白组学研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .
[10] 庞莉苹,姚江武. 抛光和上釉对陶瓷表面粗糙度、挠曲强度及磨损性能的影响[J]. 国际口腔医学杂志, 2008, 35(S1): .